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ABSTRACT
Requirement of βDELSEED-Motif of Escherichia coli F1FO ATP Synthase in
Antimicrobial Peptide Binding
by
Junior K. Tayou

F1FO ATP synthase is a membrane bound enzyme capable of synthesizing and
hydrolyzing ATP. Lately, α-helical cationic peptides such as melittin and melittin related
peptide (MRP) were shown to inhibit E. coli ATP synthase. The proposed but
unconfirmed site of inhibition is βDELSEED-motif formed by the residues 380-386,
located at the interface of α/β subunit of ATP synthase. This project was a mutagenic
analysis of βDELSEED –motif residues to understand the binding mechanism and mode
of action of peptide inhibitors. The study addressed 2 main questions: Are the
antibacterial/anticancer effects of these peptides related to their inhibitory action on ATP
synthase through interaction with the βDELSEED –motif? If so, which amino acid
residues play critical role in peptide binding?

The findings demonstrated that the βDELSEED –motif is the binding site of the above
peptides on ATP synthase and Glutamate residues are more important in peptide binding
than the Aspartate residues.
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CHAPTER 1
INTRODUCTION
Background Information on ATP Synthase

F1FO ATP synthase is a multisubunit membrane-associated enzyme complex that
is responsible for cellular energy production in animals, plants, and almost all
microorganisms by oxidative phosphorylation and photophosphorylation. In energytransducing membranes, this enzyme complex uses energy from a proton motive force
generated by the electron transport chain to catalyze the formation of ATP from ADP and
inorganic phosphate. In most prokaryotic organisms, depending on the nutritional need,
this complex can work in the reverse direction generating an electrochemical proton
gradient at the expense of ATP hydrolysis. Thus, this enzyme is capable of coupling
reversibly the hydrolysis or synthesis of ATP, respectively, with an endergonic and
exergonic efflux and influx of protons across the membrane (Boyer 1997; Fillingame et
al. 2000; Capaldi and Aggeler 2002). ATP synthase is present in all living organisms and
is located in the inner membrane of the mitochondria, the thylakoid membrane of the
chloroplast, plasma membrane of bacteria, and on the surfaces of various mammalian cell
types, including endothelial cells, adipocytes, and keratinocytes. The overall topology of
ATP synthases is well conserved in evolution. In E. coli, the molecular weight of this
enzyme is ~ 530 kDa, consisting of 2 rotary sectors, the F1 (hydrophilic or extrinsic)
portion formed by 5 polypeptides in the stoichiometry α3β3γδε and an FO (hydrophobic or
intrinsic) portion formed by three polypeptides in the stoichiometry of ab2c10 (figure 1).
On the F1 sector are located 3 active sites of this enzyme at the 3 interfaces of the α and β
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subunits that have alternating affinities for ATP, ADP and Pi. There is a high similarity in
the ATP synthase subunits from different bacteria and chloroplasts. The mitochondrial
counterpart is much more complex; 17 different types of subunits have been identified so
far. Subunits α3β3γ in the F1 portion and subunits a and c in the FO portion have high
similarity to the bacterial and chloroplast counterparts. These are the subunits that are
directly involved in proton transport, subunit rotation and ATP synthesis/hydrolysis
(Frasch 2000; Ren 2000; Noji and Yoshida 2001; Weber and Senior 2003; Ahmad and
Senior 2005; Feniouk et al. 2006; Pedersen 2007; Senior 2007).

9

Figure 1: Structure of bacterial F1FO ATP synthase by Feniouk, B.A. F1 subunits α3 and
β3 hexamer form the catalytic portion. The γ-subunit forms the shaft of the rotor. Proton
translocation take place at the interface of subunits a and c.
Figure used with permission from Feniouk 2006.

Proton flow down the gradient through FO is coupled to ATP synthesis on the F1
portion by a unique rotary mechanism. The protons flow through channels at the interface
of the a and c subunits, which drives rotation of the ring of c subunits. The c10 ring,
together with γ and ε subunits, forms the rotor while the “stator” composed of b2,
prevents the simultaneous rotation of catalytic sites and the a subunit with the rotor.

Rotation of γ leads to conformational changes in the catalytic nucleotide binding sites on
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the β subunits where ADP and Pi are bound. Proton driven clockwise rotation of the γ
subunit leads to a conformational change that results in the formation and release of ATP.
Thus, ATP synthase converts electrochemical energy, the proton gradient, into
mechanical energy in the form of subunit rotation and back into chemical energy in the
form of phosphoanhydride bonds in ATP, making this enzyme the smallest known
biological nanomotor. In E. coli this enzyme can function reversibly depending on the
physiological needs of the cell. A plasma membrane proton motive force required for
mechanical processes such as nutrient transport and locomotion can be generated by
hydrolysis of glycolytically derived ATP by the F1FO-ATPase function, with the result
that protons are pumped from the cytoplasm to the intermembrane space of the plasma
membrane (Hara et al. 2001; Noji and Yoshida 2001; Weber and Senior 2003; Wilkens
2005; Dimroth et al. 2006; Weber 2006).

Importance of This Study
ATP synthase is the fundamental means of cellular energy production in animals,
plants, and almost all microorganisms. In order to synthesize ATP, the cell‟s energy
currency, through oxidative phosphorylation and photophosphorylation, a mechanical
rotation mechanism is used in which subunits rotate at approximately 100 times per
second in order to convert foodstuffs into energy by oxidation.
Many studies have portrayed ATP synthase as a critical enzyme in human health
and in the growth of disease causing organisms in the human body. Malfunction of this
enzyme complex has been directly or indirectly associated with various disease
conditions (Hong and Pedersen 2008). A low expression of the β subunit on the F1
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portion of this complex and the accumulation of the α subunit in the cytosol of neuronal
cells is characteristic of Alzheimer‟s disease, a progressive and neurodegenetive disorder
(Sone et al. 1979; Chandrasekaran et al. 1997; Kim et al. 2000). Leigh syndrome is also
another example of a neurodegenerative disorder that is associated with a mutation in
subunit a of the FO sector of this complex leading to impaired ATP synthesis (de Vries et
al. 1993). Dysfunction of ATP synthase as a result of a mutation in the a subunit is also
implicated in ataxia, retinitis pigmentosa syndrome, and neuropathy (De Meirleir et al.
1995; Thyagarajan et al. 1995). A dysfunctional c subunit is implicated in Kufs‟ disease,
which is a lysosomal storage disease (Palmer et al. 1986). Additionally, the α subunit has
being characterized as a molecular target for innate antitumor cytotoxicity mediated by
natural interleukin 2-activated killer cells (Das et al. 1994). Intravascular circulation of
ATP synthase F6 subunit is associated with increased blood pressure (Pal and Coleman
1990).
Nonmitochondrial ATP synthases that are located on the surface of endothelial
cells, adipocytes, and keratinocytes have been shown to be involved in cell mediated
processes such as angiogenesis, pH homeostasis, lipid metabolism, and apoptosis
(Arakaki et al. 2003; Hong and Pedersen 2008; Laughlin and Ahmad 2010). These
associations make ATP synthase a good molecular target for drugs in the treatment of
different diseases and the regulation of energy metabolism. Examples of such drugs
include Benzodiazepine (Bz-423) used as a therapy for systemic lupus erythematosus, an
autoimmune disorder. Bz-423 selectively kills pathogenic lymphocytes by inducing
apoptosis in lymphoid cells. Bz-423 has been shown to bind to the oligomycin
sensitivity-conferring subunit of ATP synthase and significantly reduce its activity (Blatt,
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Bednarski et al. 2002). Diarylquinoline drugs used in treating tuberculosis are another
example, as they function through blocking the synthesis of ATP by binding to subunit c
of ATP synthase and thereby preventing rotation of the γ subunit (Andries, Verhasselt et
al. 2005). Recent studies have also shown that inhibition of nonmitochondrial ATP
synthase results in inhibition of cytosolic lipid droplet accumulation in adipocytes and
inhibition of tumor angiogenesis in endothelial cancer cells, thereby preventing their
proliferation and migration (metastasis) (Moser, Stack et al. 1999; Moser, Kenan et al.
2001; Moser, Stack et al. 2002; Arakaki et al. 2007).

Peptides and Other Inhibitors of ATP Synthase

Many organic and inorganic compounds, both natural and synthetic, have been
shown to bind and inhibit the synthetic and hydrolytic activity of ATP synthase. These
inhibitors include sodium azide, fluoroaluminate, bioflavinolic compounds, polyketide,
peptides, and a host of other organic molecules (Hong and Pedersen 2008; Dadi et al.
2009; Laughlin and Ahmad 2010). Antimicrobial α helical basic peptides such as
Melittin, (figure 3) the principal component of honeybee venom, and Melittin Related
Peptide, a frog skin peptide were shown to inhibit the growth of E. coli cells and
hydrolytic activity of both membrane-associated E. coli F1FO ATP synthase and purified
F1-ATPase (Laughlin and Ahmad 2010). The binding site of these peptides, based on
indirect evidence, is the βDELSEED-motif (figure 2) located in a loop at the carboxyl
terminal of the β subunit. This motif has been well conserved in all forms of F1 with
minor variations; DELSDED in TF1-β, DELSEED in MF1-β, and DELSEED in the β
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subunit of F1 from Escherichia coli (EF1). This loop is also highly conserved in many
species (Table 1). In the closed conformation of the β subunit, this region has contact
with the γ subunit. The complement contact region of the γ subunit is mainly in the short
helix that forms a small protrusion from the straight coiled-coil structure. Based on these
observations, the βDELSEED-motif has been assumed to play an essential role in the
rotation of the γ subunit and hence the coupling between catalysis and transport (Hara et
al 2001; Mnatsakanyan et al. 2009). The ε subunit is an intrinsic inhibitor of F1-ATPase
and it rotates along with the γ subunit. The ε subunit was unable to inhibit the F1-ATPase
activity of a mutant thermophilic ATP synthase (TF1) in which all the acidic amino acid
residues of the βDELSEED-motif were replaced by alanine residues and a similar loss of
inhibition by the ε subunit was observed when the basic residues in the C-terminal of ε
subunit were replaced by alanine residues (Hara et al. 2001).
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Figure 2a: X-ray Crystallographic structure of the βDELSEED loop showing the
negatively charged amino acids residues. This figure was generated using the PyMOL
software. The E. coli numbers for the DELSEED residues are 380 – 386.
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Figure 2b: The x-ray structure of Melittin showing the five positively charged amino acid
residues. Most AMPs are known to have α-helical-amphipathic structures similar to that
of melittin. This figure was also generated using the PyMOL software.
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Table 1: Amino acid sequence of the evolutionary conserved βDELSEED loop. The
starting residue tyrosine shown here for E. coli is βY355

Antimicrobial Peptides
Antimicrobial peptides are innate components of the immune response that are
present in all eukaryotic classes. These peptides have been shown to kill gram positive
and negative bacteria, enveloped viruses, fungi, and cancerous cells. Some of these
peptides are thought to function as immunomodulators, enhancing or repressing the
immune response. Most AMPs have a broad range of activity targeting 2 or more cellular
structures or processes (Sitaram and Nagaraj 2002).
There are over 1500 identified AMPs in the antimicrobial database, most of which
exist as α-helical amphipathic molecule of between 12 and 50 amino acid residues. They
usually contain 2 or more positively charged residues provided by arginine and/or lysine.
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This cationicity allows for ionic interaction with the phosphate head of the lipid bilayer,
while the hydrophobic amino acid residues interact with the hydrophobic tails enabling
their transport into microbial cells (Sitaram and Nagaraj 2002; Laughlin and Ahmad
2010). These membrane targeting peptides have a potent bacteriocidal activity against
multidrug resistant pathogens in a controlled environment, but little is known about their
effects within a living organism (Hancock and Sahl 2006). This selectivity might be
because the cell membranes of bacteria are more negatively charged compare to
mammalian cells; bacteria membranes are richer in acidic phospholipids, such as
phosphatidylglycerol and cardiolipin, causing AMPs to have an increased affinity to
bacterial membrane. Secondly, cholesterol is a stabilizing agent found in mammalian
plasma membranes but which is absent in bacteria membranes. Cholesterol may reduce
the activities of AMPs by stabilization of the lipid bilayer and/or its interaction with the
peptide. Additionally, the transmembrane potential of bacterial cells is more negative
than that of normal mammalian cells, making bacteria more prone to membrane
permeabilization by the insertion of positively charged AMPs (Sitaram and Nagaraj
2002; Tennessen 2005; Hancock and Sahl 2006; Matsuzaki 2008). AMPs are thought
have varied mechanisms by which they carry out their antimicrobial activities, ranging
from membrane permeabilization to effects on a range of cytoplasmic targets including
interference with metabolism (Matsuzaki et al. 1995).

Hypotheses
Recently it was shown that some AMPs including melittin, melittin related
peptide (MRP), magainin, and their derivatives differentially inhibit the hydrolytic
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activity of E. coli F1FO ATP synthase (Hong and Pedersen 2008; Laughlin and Ahmad
2010). These same peptides were also shown to differentially inhibit the growth of wild
type E. coli strain pBWU13.4/DK8, with melittin and MRP and their C-terminal amide
derivatives being more potent inhibitors compared to magainin (Laughlin and Ahmad
2010). The proposed binding site of these peptides on F1FO ATP synthase is the
βDELSEED-motif. This study was a mutagenic analysis of the βDELSEED-motif to
understand the mechanism by which these AMPs inhibit F1-ATPase. Mechanistic
knowledge of peptide binding will be helpful in understanding the
antibacterial/anticancer nature of the above peptides. The main questions were;

1. Does the inhibition of F1-ATPase by AMPs involve the binding of these AMPs to the
βDELSEED-motif? And if so,
2. Which of the amino acid residue(s) of this motif are most essential for peptide binding?

These questions were answered through substitution mutagenesis of the amino acids in
the βDELSEED-motif and comparative inhibitory biochemical assays of AMPs to wildtype and mutant F1FO ATP synthase. The acidic amino acid residues (Aspartate or
Glutamate) were changed to Alanine residues, Leucine and Serine were also changed to
Alanine, Arginine, Glutamate, or Glutamine. Comparative inhibitory biochemical assays
of AMPs to wild type and mutant F1FO ATP synthase were performed to assess the effect
of these mutations on AMP binding.
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CHAPTER 2
MATERIALS AND METHODS

Construction of Wild Type and Mutant Strains of E. coli

The wild-type strain was pBWU13.4/DK8 (Ketchum et al. 1998; Li et al. 2009).
The template for oligonucleotide-directed mutagenesis was pSN6. pSN6 is a plasmid
with the βY331W mutation from plasmid pSWM4 introduced on a SacI-EagI fragment
into pBWU13.4 (Weber et al 1993; Li et al. 2009). This plasmid was used as the template
to generate the following substitution mutations; βL382A, βL382R, βL382Q, βL382E,
βS383A, βS383R, βS383Q, βS383E, βD380A, βE381A, βE384A, βE385A, and βE386A.
Substitutions were introduced by polymerase chain reaction using the Stratagene
quikchange lightning mutagenesis kit from Agilent Technologies (catalog #210519) (see
appendix A for essential steps). The mutagenic oligonucleotides were designed using an
online (http://www.stratagene.com/qcprimerdesign) software package provided by Stratagene
(appendix D shows the forward primers for the different mutants that were designed) and
purchased from Fischer Scientific. Wild-type and mutated plasmids were transformed
into E. coli DK8 competent cells (see appendix E), which does not express E. coli ATP
synthase (Weber et al. 1993). DNA sequencing was performed on plasmids from the
transformed DK8 strains to confirm the presence of mutations and the absence of
undesired changes in sequence. It should be noted that all the mutant strains contain the
βY331W mutation, which does not affect the function of this enzyme significantly, and
the presence of this mutation was included for future studies on flourimetric estimations
of ADP and/or ATP binding and transition-state formation.
20

Measurement of Growth Yield in a Limiting Glucose Medium

Oxidative and/or photophosphorylation were measured on limiting glucose media.
Limiting glucose is a phosphate buffer containing 3–5 mM glucose with other micro- and
macronutrients (See details in appendix F). E. coli strain DK8 cells harboring wild-type
or mutated plasmids were aerobically cultivated at 37oC for 16 – 24 hours in a limiting
glucose medium and growth was measured spectrophotometrically at OD595 as in (Senior
et al. 1983; Ahmad and Senior 2005).

Preparation of E. coli Membrane Associate F1FO ATP Synthase
Wild-type or mutant E. coli membrane associate F1FO ATP synthase were isolated
and purified as in [(Senior et al. 1983; Ahmad and Senior 2005) and appendix B]. In this
procedure, loop full wild type E. coli or mutant was aerobically cultivated for 18 – 24
hours (until late log phase of growth) at 37oC, 250 rpm.
The cells were harvested by centrifugation (X2) at 9500 rpm, 4oC for 15 – 25
minutes. Prior to the second centrifugation, the cells were resuspended in STEM buffer
containing 20 mM Sucrose, and the pellet obtained was resuspended in 2 ml STEM/g of
wet cells.
20 mg of DNase was added to cells that were then resuspended in STEM. The
cells were disrupted by 2 passages through a chilled French Press cell fractionator at
20,000 psi. Cell debris were removed by centrifugation at 22,000 rpm for 20 minutes at
2oC and the membrane bound enzyme was obtained by ultracentrifugation at 60,000 rpm
for 120 minutes at 2oC.
21

The isolated membrane bound F1FO ATP synthase was washed 3 times through
ultracentrifugation at 60,000 rpm. The first wash was performed in a buffer containing
50 mM TES pH 7.0, 15% glycerol, 40 mM 6-aminohexanoic acid, 5 mM paminobenzamidine. The subsequent 2 washes were performed in a buffer containing 5
mM TES pH 7.0, 15% glycerol, 40 mM 6-aminohexanoic acid, 5 mM paminobenzamidine, 0.5 mM DTT, 0.5 mM EDTA. The final membrane bound F1FO ATP
synthase was resuspended and stored in 50 mM TrisSO4 pH 8.0, 2.5 mM MgSO4 (Noji
and Yoshida 2001).
Measurement of Membrane Associated F1FO ATP Synthase Activity
Enzyme concentrations were found by plotting the absorbance at 595 nm using
Bradford reagent against a standard bovine serum albumin curve.
F1-ATPase activity was measured in 1 ml assay buffer containing 10 mM NaATP,
4 mM MgCl2, 50 mM TrisSO4, at pH 8.5 and 37oC. Reactions were started by addition
of 20 µg membrane associated F1FO ATP synthase and stopped by addition of SDS to
3.3% (V/V) final concentration. Pi release was assayed spectrophotometrically by the
addition of T&S reagent containing 10 mM (NH4)6Mo7O24·4H2O, 250 mM
Fe(NH4)2(SO4)2·6H2O, and 1.2N H2SO4 which reacts with Pi to form a blue color
complex the intensity of which was measured at OD700 (Taussky and Shorr 1953).
The hydrolytic activity of ATP synthase in µmol/min/mg was calculated as:
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Source of Peptides and Other Chemicals
Melittin related peptide-amide (MRP-amide, an amide modified derivative of the
amphibian melittin related peptide) and Melittin-amide (an amide modified derivative of
the honey bee venom peptide melittin) were custom ordered from Biomatik. Both
peptides were received as lyophilized powder shipped on dry ice and their purity
determined by HPLC was greater than 95%. Once received, they were immediately
stored at -20oC and resuspended in autoclaved deionized water as needed. Other
chemicals used in this study were ordered from Fischer Scientific Company, Agilent
Technologies, or Sigma-Aldrich Chemical Company and were of ultra-pure analytical
grade.

Inhibition of ATPase Activity by Amphibian Melittin Related Peptide-Amide or Honey
Bee Venom Peptide Melittin-Amide
Wild-type or mutant membrane bound F1Fo ATP synthase were preincubated with
varied concentrations of MRP-amide or melittin-amide for 60 minutes at room
temperature in 50 mM TrisSO4 pH 8.0. 500 µl ATPase assay buffer contained 10 mM
NaATP, 4 mM MgCl2, 50 mM TrisSO4, and pH 8.5. The reaction was stopped by the
addition of SDS to a final concentration of 3.3% (v/v). The addition of an equal volume
of T&S reagent gave rise to a blue color that was assayed spectrophotometrically at
OD700. Inhibitory exponential decay and piecewise curves were generated with Sigma
plot 10.0 (Taussky and Shorr 1953; Laughlin and Ahmad 2010).
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CHAPTER 3
RESULTS

Growth Properties of βD380A, βE381A, βE384A, βE385A, and βD386A Mutants of E.
coli ATP Synthase
βD380A, βE381A, βE384A, βE385A, and βD386A mutants were generated and
the presence of the desired mutations and absence of unwanted mutations were confirmed
through sequencing of the C-terminal of the β-subunit. The Glutamate and Aspartate
residues shown here are highly conserved in the βDELSEED-loop (figure 2 and Table 1)
of ATP synthase from all sources and organisms. βD380A, βE381A, βE384A, βE385A,
and βD386A mutations were designed to understand the possible effect of the smaller
neutral side chain of Alanine in the binding/inhibition by AMPs.

The introduction of βE384A or βD386A mutation resulted in approximately 26%
or 32% loss of oxidative phosphorylation respectively, but the growth yield of βD380A,
βE381A, and βE385A was within ±15% that of the wild-type (Table 2). This slight loss
in oxidative phosphorylation might be caused by the fact that the βDELSEED motif is
not located in catalytic site of this enzyme.
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Table 2: Growth Properties of βD380A, βE381A, βE384A, βE385A, and βD386A
Mutants of E. coli ATP Synthase on Limiting Glucose

Strains

Mutations

Growth yield on limiting glucose

pBWU13.4
(Wild type)
pSN6

-

100

βY331W

98

pUC118
(Null)
pJT01

-

42

βD380A/ βY331W

92

pJT04

βE381A/ βY331W

93

pJT17

βE384A/ βY331W

84

pJT20

βE385A/ βY331W

91

pJT23

βD386A/ βY331W

81

*Wild type (pBWU13.4/DK8) contains UNC+ gene encoding ATP synthase; Null
(pUC118/DK8) with UNC− gene and lacks ATP synthase.
Table 2 shows the effects of βD380A, βE381A, βE384A, βE385A, or βD386A mutation
on cell growth in a limiting glucose media. Limiting glucose contain 3 – 5 mM Glucose
(see materials and method and appendix F). βD380A, βE381A, βE384A, βE385A, or
βD386A mutant was expressed with βY331W also present, which has being shown to
significantly affect cell growth (Weber and Senior 2003; Ahmad and Senior 2005; Li et
al. 2009). Each data point is the mean of 4 experimental values.
Growth Properties of βL382A, βL382R, βL382Q, βL382E, βS383A, βS383R, βS383Q,
and βS383E Mutants of E. coli ATP Synthase
The introduction of βL382A, βL382R, βL382Q, βL382E, βS383A, βS383R,
βS383Q, or βS383E mutation resulted in between 2 and 17% loss of growth on a limiting
glucose media (Table 3). This slight loss in oxidative phosphorylation again might be
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caused by the fact that the βDELSEED motif is not located in catalytic site of this
enzyme.
Table 3: Effects of βL382A, βL382R, βL382Q, βL382E, βS383A, βS383R, βS383Q, or
βS383E mutation on cell growth in a limiting glucose media.

Strains

Mutations

Growth yield on
Limiting Glucose

pBWU13.4

-

100

pSN6

βY331W

98

pUC118

-

42

pJT07

βL382A/ βY331W

90

pJT08

βL382R/ βY331W

85

pJT09

βL382Q/ βY331W

83

pJT11

βL382E/ βY331W

89

pJT12

βS383A/ βY331W

95

pJT13

βS383R/ βY331W

85

pJT14

βS383Q/ βY331W

93

pJT16

βS383E/ βY331W

93

*Wild type (pBWU13.4/DK8) contains UNC+ gene encoding ATP synthase; Null
(pUC118/DK8) with UNC− gene and lacks ATP synthase.
Table 3 shows the effects of βL382A, βL382R, βL382Q, βL382E, βS383A, βS383R,
βS383Q, or βS383E mutation on cell growth in a limiting glucose media. Limiting
glucose contain 3 – 5 mM Glucose (see materials and method and appendix F). Each data
point is the mean of 4 experimental values.
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ATPase Activity of Wild Type and Mutant F1FO ATP Synthase
Specific F1-ATPase activities of membrane preparations containing mutant enzymes were
compared with wild type and null control at 37oC (Table 4). Introduction of βL382Q
reduced the ATPase activity by 2 fold while the other mutations that were introduced into
this βDELSEED motif resulted in approximately 4 – 5 fold loss of ATPase activity.

Table 4: ATPase Activity of Wild Type and Mutant F1FO ATP Synthase
Strains

Mutations

ATPase Activity
(µmol/mg/min)

WT

-

DELSEED

20

pJT01

βD380A/ βY331W

AELSEED

4.7

pJT04

βE381A/ βY331W

DALSEED

2.9

pJT17

βE384E/ βY331W

DELSAED

5.3

pJT20

βE385A/ βY331W

DELSEAD

6.6

pJT23

βE386R/ βY331W

DELSEEA

3.5

pJT07

βL382A/ βY331W

DEASEED

5.7

pJT08

βL382R/ βY331W

DERSEED

7.4

pJT09

βL382Q/ βY331W

DEQSEED

12.5

pJT11

βL382E/ βY331W

DEESEED

4.8

pJT12

βS383A/ βY331W

DELAEED

3.4

pJT13

βS383R/ βY331W

DELREED

4.6

pJT14

βS383Q/ βY331W

DELQEED

4.1

pJT16

βS383E/ βY331W

DELEEED

6.9

Null

-

-

0

Table 4 shows ATPase Activity of wild type and mutant enzymes. The ATPase activity
was measured at 37°C and expressed as μmol of ATP hydrolyzed/min/mg of protein
present. Each individual experimental point is the mean of duplicate assay tubes.
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Inhibition of ATPase Activity of Membrane bound βD380A and βD386A Mutant F1FO
ATP Synthase by Melittin-Amide and MRP-Amide
Figure 3a shows the inhibition of ATPase activity of pJT01/DK8 (βD380A, or
AELSEED) and figure 3b pJT23/DK8 (βD386A, or DELSEEA) membrane bound F1FO
ATP synthase in the presence of varied concentrations of melittin-amide. The results with
the wild type enzyme was within ± 10% that reported in previous studies involving
inhibition of wild type (pBWU13.4/DK8) F1FO ATP synthase with Melittin-amide (Li et
al. 2009). The result also shows that in the presence of βD380A or βD386A mutation, the
inhibitory profile with melittin-amide was significantly changed. 20 µM melittin-amide
inhibited 75% of wild type (DELSEED) activity, 30% of pJT01/DK8 (AELSEED), and
28% of pJT23/DK8 (DELSEEA) activity.

Figure 3a: βD380A (AELSEED)

Figure. 3b: βD380A (DELSEEA)

Figure 3: Inhibition of ATPase activity in F1FO ATP synthase by melittin-amide on; the
membrane bound enzymes were preincubated with varied concentration of melittinamide for 60 min at 26 °C and then 1 ml of assay buffer was added and ATPase activity
determined. See details in material and methods. Symbols used are: (○, Wild-type
(DELSEED) and Δ, βD380A (AELSEED) or βD386A (DELSEEA)). Each data point
represents average of at least 2 experiments done in duplicate and results agreed within
±10%.
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Figure 4a shows the inhibition of ATPase activity of pJT01/DK8 (AELSEED)
and Figure 4b pJT23/DK8 (DELSEEA) membrane bound F1FO ATP synthase in the
presence of varied concentrations of MRP-amide. The results with the wild-type enzyme
was within ± 10% of that reported in previous studies involving inhibition of the wildtype strain (pBWU13.4/DK8) with MRP-amide (Laughlin and Ahmad 2010). The result
also shows that in the presence of βD380A or βD386A mutation, the inhibitory profile
with MRP-amide was significantly changed. 20 µM MRP-amide was inhibited to 70% of
wild type (DELSEED) ATPase activity, 58% of pJT01/DK8 (AELSEED), and 50% of
pJT23/DK8 (DELSEEA) ATPase activity.

Figure 4a: βD380A (AELSEED)

Figure 4b: βD380A (DELSEEA)

Figure 4: Inhibition of ATPase activity in F1FO ATP synthase by MRP-amide. Symbols
used are: (○, Wild type (DELSEED) and Δ, βD380A (AELSEED) or βD386A
(DELSEEA)). Each data point represents average of at least 2 experiments done in
duplicate and results agreed within ±10%.
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Inhibition of ATPase Activity of Membrane bound βE381A, βE384A and βE385A
Mutant F1FO ATP Synthase by Melittin-Amide and MRP-Amide
Figure 5a shows the inhibition of ATPase activity pJT04/DK8 (DALSEED),
Figure 5b: pJT17/DK8 (DELSAED) and Figure 5c: pJT20/DK8 (DELSEAD) of
membrane bound F1FO ATP synthase in the presence of varied concentrations of melittinamide. The result also shows that in the presence of βE381A, βE384A, or βE385A
mutation, the inhibitory profile with MRP-amide was significantly changed. 20 µM
melittin-amide inhibited 5% of pJT04/DK8 (DALSEED), 20% of pJT17/DK8
(DELSEAD), and 22% of pJT20/DK8 (DELSEAD) ATPase activity.

Figure 5a: βE381A (DALSEED)

Figure 5b: βE384A (DELSAED)

Figure 5c: βE385A (DELSEAD)
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Figure 5: Inhibition of ATPase activity in F1FO ATP synthase by melittin-amide.
Symbols used are: (○, Wild type (DELSEED) and Δ, βE381A (DALSEED), βE384A
(DELSAED), or βE385A (DELSEAD)). Each data point represents average of at least 2
experiments done in duplicate and results agreed within ±10%.

Figure 6c shows the inhibition of ATPase activity of pJT04/DK8 (DALSEED),
Figure 6b: pJT17/DK8 (DELSAED) and Figure 6c: pJT20/DK8 (DELSEAD) membrane
bound F1FO ATP synthase in the presence of varied concentrations of MRP-amide. The
result also shows that in the presence of βE381A, βE384A, or βE385A mutation the
inhibitory profile with MRP-amide was significantly changed. 20 µM MRP-amide was
inhibited to 40% of pJT04/DK8 (DALSEED), 25% of pJT17/DK8 (DELSEAD), and
55% of pJT20/DK8 (DELSEAD) ATPase activity.
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Figure 6a: βE381A (DALSEED)

Figure 6b: βE384A (DELSAED)

Figure 6c: βE385A (DELSEAD)
Figure 6: Inhibition of ATPase activity in F1FO ATP synthase by MRP-amide. Symbols
used are: (○, Wild type (DELSEED) and Δ, βE381A (DALSEED), βE384A
(DELSAED), or βE385A (DELSEAD)). Each data point represents average of at least 2
experiments done in duplicate and results agreed within ±10%.
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Inhibition of ATPase Activity of Membrane bound βL382A, βL382R, βL382Q or
βL382E, Mutant F1FO ATP Synthase by MRP-Amide
The introduction of βL382A or βL382Q mutation did not significantly change the
inhibitory profile compared to wild-type. The introduction of βL382R mutation resulted
in a significant loss of inhibition by MRP-NH2. Interestingly 20 µM MRP-NH2 inhibited
82% of βL382E mutant ATPase activity compared to 76% activity in wild-type (figure
7).

Figure 7a: βL382A (DEASEED)

Figure 7b: βL382R (DERSEED)

Figure 7c: βL382Q (DEQSEED)

Figure 7d: βL382E (DEESEED)

Figure 7: Inhibition of ATPase activity in F1FO ATP synthase by MRP-amide. Symbols
used are: (○, Wild type (DELSEED) and Δ, βL382A (DEASEED), βL382R (DERSEED),
βL382Q (DEQSEED), or βL382A (DEESEED)). Each data point represents average of at
least 2 experiments done in duplicate and results agreed within ±10%. Spectroscopic
readings were obtained using Synergy HT spectrophotometer from Biomatik.
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Inhibition of ATPase Activity of Membrane bound βS383A, βS383R, βS383Q or βS383E
Mutant F1FO ATP Synthase by MRP-Amide
The introduction of βS383A or βS383R mutation did not significantly change the
inhibitory profile compared to wild-type. But contrary to what was expected, 20 µM
MRP-NH2 could not significantly inhibit the ATPase activity of βS383E mutant enzyme.

Figure 8a: βS383A (DELAEED)

Figure 8b: βS383R (DELREED)

Figure 8c: βS383Q (DELQEED)

Figure 8d: βS383E (DELEEED)

Figure 8: Inhibition of ATPase activity in F1FO ATP synthase by MRP-amide. Symbols
used are: (○, Wild type (DELSEED) and Δ, βS383A (DELAEED), βS383R (DELREED),
βS383Q (DELQEED), or βS383E (DELEEED)). Each data point represents average of at
least 2 experiments done in duplicate and results agreed within ±10%. Spectroscopic
readings were obtained using Synergy HT spectrophotometer from Biomatik.
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CHAPTER 4
DISCUSSION
The purpose of this study was to examine the mechanism by which α-helicalamphipathic antimicrobial peptides bind and inhibit F1FO ATP synthase. Previously, it
was shown that some insect and amphibian antimicrobial peptides differentially bind and
inhibit F1-ATPase activity (Laughlin and Ahmad 2010). It was proposed that the binding
site of these peptides on F1FO ATP synthase was the conserved βDELSEED-motif found
at the carboxyl terminal domain of the beta subunit (Table 1 and figure 2). This motif
was previously identified as the binding site for many peptide inhibitors (Hong and
Pedersen 2008). Melittin or cationic phenothiazine was shown to bind to calmodulin, a
calcium binding protein expressed in many eukaryotic cells, by interacting with the
negatively charged sequence EEEIRE, which resembles the negatively charge
βDELSEED-motif
(Malencik and Anderson 1984; Gresh and Pullman 1986; Strynadka and James 1988).
Also ε-subunit, an intrinsic inhibitor of F1-ATPase that is characterized by the presence
of positively charge amino acid residues at its carboxyl terminus, was shown to exert its
inhibitory effect by ionic interactions with the βDELSEED-motif (Noji and Yoshida
2001).
We introduced the following mutations βL382A, βL382R, βL382Q, βL382E,
βS383A, βS383R, βS383Q, βS383E, βD380A, βE381A, βE384A, βE385A, and βE386A
to examine the requirement of the βDELSEED-motif in peptide binding and the role
played by individual amino acid residues in this binding mechanism. Introduction of any
of the said mutations resulted in a loss of between 5 - 18% of growth in a limiting glucose
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medium (Tables 2 and 3). The probable reason for this relatively small decrease in
growth compared to previous mutational studies of ATP synthase (Li et al. 2009) is that
the βDELSEED residues are not present in the active site of the enzyme.
The introduction of βD380A (AELSEED), βE381A (DALSEED), βE384A
(DELSAED), βE385A (DELSEAD), or βE386A (DELSEEA) resulted in a change in the
inhibitory profile by melittin-NH2 and MRP-NH2 compared to the wild-type
(DELSEED). The inhibition of E. coli F1FO ATP synthase after the introduction of either
of these mutations was characterized by a „biphasic‟ inhibitory profile; at concentrations
< 10 µM the peptides did not inhibit F1-ATPase activity of these mutants, but as the
inhibitor concentrations were increased there were changes in the inhibitory profiles. This
can be explained by the fact that either of these mutations resulted in a decrease in the
number of negative charge amino acid residues in the βDELSEED-motif, likely making it
less favorable for melittin-NH2 and MRP-NH2 at concentrations of < 10 µM to effectively
bind and inhibit ATP synthase. But as the concentrations were increased the positively
charged peptides did bind at the other negatively charged amino acid residues and thus
inhibit F1-ATPase activity.
The introduction of the βL382E mutation resulted in a slight increase in the
inhibition of F1-ATPase activity by MRP-NH2 (figure 7) suggesting that Leucine at
position 382 on the β subunit might be providing a steric hindrance and thereby
preventing tight binding of AMPs at the βDELSEED-motif. Introduction of βS383E
resulted in a complete loss of inhibition of F1-ATPase activity by MRP-NH2 (figure 8).
This was contrary to what was expected. Because this mutation resulted in an increase in
number of negatively charged amino acids, it was expected that there will be tighter
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binding of the inhibitor unto this motif. The basis of this observation is unknown because
this mutant enzyme had an activity of 6.9 µmolmin-1mg-1 (Table 4) and the growth of the
bacteria harboring this mutated enzyme on limiting glucose media was close to that of the
wild type (Table 3), which suggests an intact functional enzyme.
The results also show that for each of the mutated enzymes, there was less F1ATPase activity in the presence of 20 µM MRP-NH2 than in the presence of 20 µM
Melttin-NH2. This implies that MRP-NH2, having 3 basic amino acid residues, requires
the presence of fewer acidic amino acid residues to exert its effect compare to MelittinNH2 with 5 basic amino acid residues.
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APPENDICES
Appendix A
Quikchange Lightning Mutagenesis Procedure
The steps outlines here were used to generate the mutated plasmid used in this
study. These steps are part of a protocol supplied with the mutagenesis kit from
Stratagene purchased from Agilent Technologies catalog #210519.
Into a thin-walled reaction tube, add


5 μl of 10× reaction buffer



75 ng of dsDNA template



125 ng of oligonucleotide forward primer



125 ng of oligonucleotide reverse primer



1 μl of dNTP mix



1.5 μl of QuikSolution reagent



ddH2O to a final volume of 50 μl

Then add:


1 μl of QuikChange Lightning Enzyme

PCR of reaction mix

Segment
1
2

Cycles
1
18

Temperature
95oC
95oC
60oC
68oC

3

1

68oC

45

Time
2 minutes
20 seconds
10 seconds
30 seconds/kb of
plasmid
5 minutes



Add 2 μl of Dpn I restriction enzyme directly to each amplification reaction. Dpn
I digest the parental plasmid which is dam methylated.



Pipette up and down the reaction mixture several times and immediately incubate
at 37oC for 15 minutes to digest parental supercoiled dsDNA.

Transformation of XL10-Gold Ultracompetent Cells


Place XL10-Gold ultracompetent cells on ice and allow to thaw.



For each sample reaction to be transformed,
o Aliquot 45 μl of the ultracompetent cells to a prechilled 14-ml BD Falcon
polypropylene round-bottom tube.
o Add 2 μl of the β-mercaptoethanol mix to the 45 μl of cells.
o Swirl the contents of the tube gently and incubate on ice for 2 minutes.
o Transfer 2 μl of the Dpn I-treated DNA from each control and sample
reaction to separate aliquots of the ultracompetent cells.
o Swirl the transformation reactions gently to mix and incubate the reactions
on ice for 30 minutes.
o Heat-pulse the tubes in a 42°C water bath for 30 seconds. Do not exceed
42°C.
o Incubate the tubes on ice for 2 minutes.
o Add 0.5 ml of preheated (42°C) NZY+ broth to each tube and then
incubate the tubes at 37°C for 1 hour with shaking at 250 rpm.



Plate the appropriate volume of each transformation reaction on agar plates
containing the appropriate antibiotic for the plasmid vector, in my case ampicillin.
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Appendix B
A Schematic Representation of Preparation of Membrane Bound F1FO ATP Synthase


Overnight E. coli cultures



Centrifuge pellet at
9500 rpm x 15 min



Resuspend pellet in STEM
Spin at 9500 rpm x 25 min



Resuspend pellet in 2 ml STEM/g wet cells
Add DNase to the pellet and French Press twice at
20 K x 3-6 minutes



Centrifuge at22K rpm x 20 minutes



Centrifuge supernatant at
60K rpm x 3 hrs at 2oC



Resuspend pellet in TES 50
Spin at 60K rpm x 3 hrs at 2oC



Resuspend pellet in TES 5 + PBA
Spin at 60K rpm x 2 hrs at 2oC
(Repeat this step)



Resuspend in 50 mM TrisSO4 pH 8.0, 2.5 mM MgSO4
Store at -70oC or -20oC for short-term usage
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Appendix C
List of Antimicrobial Peptides

Table A3: A list of peptides with antimicrobial peptides that were shown to differential
inhibits F1-ATPase activity. Melittin-amide and MRP-amide were shown to inhibit more
90% of ATPase activity, Magainin II- amide 60%, and Caerin 1.8 0%. Melittin-amide
and MRP-amide were the 2 inhibitors that were used in this study.

AMPs

Sequence

length

Net positive
charge

Melittin-

GIGAVLKVLTTGLPALISWIKRKRQQ-NH2

26

5

MRP-amide

AIGSILGALAKGLPTLISWIKNR-NH2

23

3

Magainin II-

GIGKFLHSAKKFGKAFVGEIMNS-NH2

23

4

GLFKVLGSVAKHLLPHVVPVIAEK

24

3

amide

amide
Caerin 1.8
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Appendix D

List of Oligonucleotide Used for Site Directed Mutagenesis

The forward and reverse primer for site directed mutagenesis were designed using online
software provide by Agilent Technologies (www.genomics.agilent.com). The primers
were between 25 and 45 bases in length, with a melting temperature (Tm) of ≥78°C. The
underline bases show the introduction of the desired mutation.
Strain
WT ( pBWU13.4)
pSN6

Mutation
βY331W
βD380A

βDELSEED
βDELSEED
βAELSEED

βE381A

βDALSEED

βL382A

βDEASEED

βL382R

βDERSEED

βL382Q

βDEQSEED

βL382E

βDEESEED

βS383A

βDELAEED

βS383R

βDELREED

βS383Q

βDELQEED

βS383E

βDELEEED

βE384A

βDELSAED

βE385A

βDELSEAD

βE386A

βDELSEEA

pJT01
pJT04
pJT07
pJT08
pJT09
pJT11
pJT12
pJT13
pJT14
pJT16
pJT17
pJT20
pJT23

49

Forward Primer
NA
NA
CGCCATCCTGGGTATGGCTGAACT
GTCTGAAGAAG
CATCCTGGGTATGGATGCACTGTC
TGAAGAAGACA
GCCATCCTGGGTATGGATCGACT
GTCTGAAGAAGAC
CCTGGGTATGGATGAACGGTCTG
AAGAAGACAAAC
CTGGGTATGGATGAACAGTCTGA
AGAAGACAAC
CGCCATCCTGGGTATGGATGAAGAGTCT
GAAGAAGAC
CTGGGTATGGATGAACTGGCTGAAGAAG
ACAAACTGG
CCTGGGTATGGATGAACTGCGTGAAGAA
GACAAACTGGTG
CATCCTGGGTATGGATGAACTGCAGGAA
GAAGACAAACTGGTGGTAG
CATCCTGGGTATGGATGAACTGGAGGAA
GAAGACAAACTGGTGGTAG
GTATGGATGAACTGTCTGCAGAAGACAC
AAACTGGTGGT
GGATGAACTGTCTGAAGCAGACA
ACTGGTGGTAG
GAACTGTCTGAAGAAGCCAAACT
GGTGGTAGCGC

Appendix E

Electrotransformation of E. coli DK8 Strains

E. coli DK8 was transformed by electroporation using the MicroPulser electroporation
apparatus from Bio-Rad cat # 165-2100.

Preparation of Electrocompetent Cells


Inoculate 500 ml of LB-broth with 5 ml of a fresh overnight culture of E. coli.



Grow the cells at 37oC shaking at 300 rpm to an OD600 of ~0.6 (NB: the best
results are obtained when the cells are harvested during mid-log phase in growth.)



Keep cell on ice for 20 minutes. All subsequent steps are performed as close to
0oC as possible.



Harvest the cells by centrifuging at 500 rpm for 15 minutes at 4oC.



Pour off the supernatant and resuspend the cells in 500 ml of ice-cold 10%
glycerol.



Centrifuge at 5000 rpm for 15 minutes at 4oC and discard the supernatant.



Resuspend the cells in 250 ml ice-cold 10% glycerol, centrifuge at 5000 rpm for
15 minutes at 4oC and pour off the supernatant.



Resuspend the cells in 250 ml of ice-cold 10% glycerol, transfer to a 30 ml sterile
Oakridge tube, centrifuge at 5000 rpm for 15 minutes at 4oC and discard the
supernatant.



Resuspend the cell in final volume of 5% glycerol. The cell concentration should
be about 1-3 x 1010 cells/ml.
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The cells can be transformed immediately or stored in aliquots on dry ice and
stored at -70oC for at least 6 months stability.
Electroporation



In cold, 1.5 ml microfuge tube, mix 40 µl of the cell suspension and 2 µl of DNA.
Mix and incubate on ice for ~1 minute.



Set the MicroPulser to Ec1, Ecl2, or 3 when using a 0.1 or 0.2 cm cuvette
respectively and pulse once with the cuvette sitting in the chamber slide.



Remove the cuvette from the chamber and immediately add 1 ml of SOC medium
to the cuvette.



Transfer the cell suspension to a 17x100 mm polypylene tube and incubate at
37oC for ~1 hour, shaking at 225 rpm.



Plate on selective medium; in my case ampicillin.
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Appendix F
Buffers, Reagents, and Culture Media

The following quantities represent what is required for 1000 ml preparation

Argenine Ent Thimine
Use in preparing limiting and minimal glucose media


To 800 ml ddH2O add



6.17 g 2,3 Dihydroxy Benzoic acid



168.6 g L-Arginine



10 ml 20 mM Thiamine



Add NaOH to completely dissolve the solutes



Make final volume to 1000 ml with ddH2O



Filter sterile and store at room temperature

ATPase assay buffer

Use as an ATP generating solution to measure ATPase activity



To 850 ml ddH2O add



50 ml 1 M Tris



4 ml 1M MgCl2



25 ml 0.4 Na ATP (Adenosine 5-triphosphate disodium salt)



Adjust pH to 8.5 with H2SO4
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Bring to a final volume of 1000 ml with ddH2O



Store in plastic bottles at -20oC

Isoleucine-Valine
Essential for bacteria growth, use in preparing limiting and miminal glucose media


To 900 ml ddH2O add



3.94 g Isoleucine



3.52 g Valine



Make final volume to 1000 ml with H2O



Filter sterile and store at room temperature

LB ampicillin liquid media
Use to ensure selectivity since the plasmids contain ampicillin resistance gene


20 g of LB broth powder



Add H2O to bring to 1000 ml



Autoclave for 30 minutes



Cool the media to ~55oC



Add 1000 μl of 100 mg/ml Ampicillin and store at 4oC

LB-agar (Solid) medium
To grow bacteria


20 g of LB broth powder



Add 15g of agar
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Add ddH2O to bring to 1000 ml



Autoclave for 30 minutes



Cool the media to ~55oC



Add 1000 μl of 100 mg/ml Ampicillin



Pour into approximately 30 petridishes and store at 4oC

Minimal Glucose Growth Media
Growth media use in cultivating bacteria prior to membrane bound enzyme purification


To 850 ml ddH2O add



10.45 g Potassium Phosphate Dibasic Trihydrate (K2HPO4)



4.8 g Sodium Phosphate Monobasic (NaH2PO4)



1.98 g Ammonium Sulfate ((NH4)2SO4)



Autoclave for 30 min, cool it to room temperature and add the following additions
o 20 ml Uracil
o 20 ml 27 % Glucose (Final glucose concentration of 10 mM)
o 10 ml ILV (isoleucin-valine)
o 1 ml TE (trace elements)

Store at 4oC
NB: Preparation of limiting glucose media requires the addition of 6 ml of 27% Glucose
solution to 1 liter of minimal media to have a glucose concentration of 3mM.

NZY+ Broth
Use in enhancing transformation of XL10-Gold Ultracompetent Cells
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10 g of NZ amine (casein hydrolysate)



5 g of yeast extract



5 g of NaCl



Add ddH2O to a final volume of 1 liter



Adjust to pH 7.5 using NaOH



Autoclave

Add the following filer-sterilized supplements prior to use:


12.5 ml of 1 M MgCl2



12.5 ml of 1 M MgSO4



20 ml of 20% (w/v) glucose (or 10 ml of 2 M glucose)

10 % SDS
Use in stopping in vitro hydrolysis of ATP by ATP synthase


1000 mg Sodium dodecyl sulfate



Bring to a final volume of 1000 ml with ddH2O and store at room temperature

SOC
Use in enhancing electrotransformation of E. coli DK8


To 865 ml of ddH2O add



20 g tryptone



5 g yeast extract



0.5 g NaCl
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20 ml of 1 M glucose



Autoclave and add
o

10 ml 0.25M KCl

o

5 ml 2M MgSO4

o

100 µl 5M NaOH

STEM
Use as a buffer to facilitate cell lyses during French press


To 700 ml ddH2O add



100 ml 1 M TES



4.29 g Mg(CH3COO)2·4H2O



85.5 g sucrose



0.0951 g EGTA (Ethylene glycol-bis-(2-aminoethylether)-N,N,N,N-tetraacetic
acid)



5 g EACA (6-Ainocaproic acid6-Ainocaproic acid)



Adjust pH to 6.5 with NaOH



Bring to a final volume of 1000 ml with ddH2O



Store in plastic bottles at -20oC

TES 50
Use as a washing buffer during enzyme purification


To 700 ml ddH2O add



50 ml 1 M TES
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150 ml glycerol



5 g 6-Ainocaproic acid 6-Ainocaproic acid (EACA)



1 g 4-Aminobenzamidine dihydrochloride (PAB)



Adjust pH to 6.5 with NaOH



Bring to a final volume of 1000 ml with ddH2O



Store in plastic bottles at -20oC

TES 5 + PAB
Use as a washing buffer during enzyme purification


To 700 ml ddH2O add



5 ml 1 M TES



150 ml glycerol



1 ml 0.5 M Dithiothreitol (DTT)



5 g 6-Ainocaproic acid6-Ainocaproic acid (EACA)



1 g 4-Aminobenzamidine dihydrochloride (PAB)



2.5 ml 0.2 M Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA)



Adjust pH to 6.5 with NaOH



Store in plastic bottles at -20oC

Trace Elements
Use in preparing limiting and minimal glucose media


To 850 ml ddH2O



2.51 g Zinc Sulfate (ZnSO4.7H2O)



0.17 g Manganese Sulfate (MnSO4.H2O)
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0.29 g Boric acid (H3BO3)



0.12 g Calcium Sulfate (CaSO4.2H2O)



0.37 g Calcium Chloride (CaCl2.2H2O)



0.49 g Ferric Chloride (FeCl3.6H2O)



Make final volume to 1000 ml with ddH2O.



Filter sterile and store at room temperature

50 mM Tris-SO4 buffer
Reaction buffer for ATPase activity assay


To 850 ml ddH2O add



6.1 g Tris



Adjust pH to 8.0 with H2SO4



Bring to a final volume of 1000 ml with ddH2O



Store at room temperature

(Taussky and Shorr) T&S reagent


Solution A: 12 g Ammonium molybdate ((NH4)6Mo7O24·4H2O in 98 ml 12 N
H2SO4)



Solution B: 100 g Ferrous ammonium sulfate (Fe(NH4)2(SO4)2·6H2O in 700 ml
H2O)



Add solution A to solution B while stirring



Bring to a final volume of 1000 ml with ddH2O



Store at 4oC
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